LifeMD Inc (LFMD) — Titan Protect Analysis

LFMD

LifeMD Inc

Healthcare · ·

$4.89

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$218M

Total market value of the company

Trailing P/E

N/A

Forward P/E

8.76

Based on estimated future earnings — lower means cheaper

Rev Growth

-1.4%

Year-over-year revenue change

Profit Margin

2.9%

How much profit the company keeps from each dollar of revenue

ROE

-238.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+104% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About LifeMD Inc

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides vi

https://lifemd.com

Country: United States Employees: 347 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.203

Positive but modest risk-adjusted returns

Kelly Fraction

0.0078

Marginal edge — very small allocation suggested

Calmar Ratio

-0.281

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-23.2%

Historical annualised return based on price data

Max Drawdown

-82.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.02

Significantly more volatile than the market

52W High

$15.84

69% below the year high

52W Low

$2.56

91% above the year low

Avg Volume

1,242,680

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.44

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

41.05

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

86.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-17.8%

Profit from core operations before interest and tax

Free Cash Flow

$-4,156,398

Negative — the business is spending more than it generates

Revenue (TTM)

$193M

Total revenue over the last 12 months

Net Income

$-21,299,564

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$15.00

Target Median

$10.00

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go